TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Börse Stuttgart
Equities
2TZ
CNE100000924
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.214 EUR | -5.49% |
|
-6.80% | +22.04% |
| 05-15 | Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Announces Directorate and Committee Changes | CI |
| 04-30 | Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3% | MT |
Strengths
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With a 2024 P/E ratio at 23.13 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +22.04% | 3.28B | - | ||
| +32.48% | 5.8B | B- | ||
| -26.22% | 3.92B | C+ | ||
| -20.86% | 2.77B | B- | ||
| -11.88% | 2.26B | - | D+ | |
| +46.64% | 1.95B | - | ||
| -16.71% | 1.52B | - | - | |
| +44.65% | 1.49B | - | ||
| -9.60% | 1.49B | - | - | |
| -22.88% | 1.35B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600329 Stock
- 2TZ Stock
- Ratings Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited
